Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Operating Expenses (2018 - 2025)

Neurogene's Operating Expenses history spans 6 years, with the latest figure at $27.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 27.97% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $103.3 million, up 23.7%, while the annual FY2025 figure was $103.3 million, 23.7% up from the prior year.
  • Operating Expenses reached $27.5 million in Q4 2025 per NGNE's latest filing, up from $23.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $27.5 million in Q4 2025 to a low of $12.6 million in Q2 2023.
  • Average Operating Expenses over 3 years is $20.2 million, with a median of $21.3 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: surged 67.19% in 2024, then rose 7.29% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $14.7 million in 2023, then surged by 46.01% to $21.5 million in 2024, then increased by 27.97% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Operating Expenses are $27.5 million (Q4 2025), $23.8 million (Q3 2025), and $26.1 million (Q2 2025).